Sonoma Pharmaceuticals (SNOA) Revenue by Segment

Breaks revenue into business lines or product groups (for example, prescription products, over‑the‑counter brands, and contract manufacturing). Highlights which segments drive sales and margins, and uncovers concentration risk if a single product or customer dominates. Growing revenue from diversified or recurring segments suggests more stable cash flow and a clearer path to valuation upside.

Human Care has become the clear growth engine, delivering a step‑change in 2024–26 and driving most of the company’s revenue upside; Animal Care is flat and not keeping pace, suggesting limited diversification. The abrupt disappearance of the “Other” line after mid‑2025 looks like a divestiture or reclassification, concentrating risk in Human Care. For investors, sustainability of Human Care’s gains (organic demand, pricing, or M&A) and margin impact are the key items to watch.